The event, dated and filed, came in late June. Anixa Biosciences, the San Jose company “focused on the treatment and prevention of cancer,” put out word that it “today announced that the Korean Ministry of Intellectual Property (MOIP) has issued Patent Number 10-2960889 related to Anixa’s breast cancer vaccine technology”. In the company’s words, “This composition-of-matter patent, exclusively licensed from Cleveland Clinic, protects the Company’s novel approach to breast cancer prevention and treatment in South Korea through 2040”, all of it “expanding the Company’s growing global IP estate”. The salient line for anyone outside the patent bar is the one the release states almost in passing: the vaccine addresses “a disease for which no preventive vaccine is currently approved anywhere in the world”. A patent, in other words, is a promise with a filing number.
The premise, stripped of the press-release varnish, is precise. The vaccine works by “immunizing against human α-lactalbumin, a protein associated with lactation that is aberrantly expressed in certain types of breast cancer”, and the strategy “aims to selectively prime the immune system to prevent tumor formation while avoiding harm to normal tissue”, “particularly in aggressive forms of the disease such as triple-negative breast cancer”. Why Korea is worth its own grant is set out plainly: “While breast cancer survival rates are high in South Korea, the incidence rate has been increasing rapidly and, unlike in Western nations, the disease tends to occur earlier in life heightening the need for preventive options in the region”. The evidence, for now, is early: in the completed Phase 1 at Cleveland Clinic, per the chief executive, “the vaccine met all major primary endpoints, was safe and well tolerated, and generated immune responses in 74% of participants”. A Phase 1 is a beginning, not a verdict; the release, to its credit, does not pretend otherwise.
The company behind the grant is a curiosity in itself. “Tracing its origins back to an incorporation in 1982, the company initially operated as ITUS Corporation before adopting the name Anixa Biosciences, Inc. in October 2018”. Dr. Amit Kumar, Anixa’s chairman and chief executive, framed the Seoul grant as scaffolding: “Each global patent we secure deepens the global foundation we are building for our breast cancer vaccine”, and he added that “our growing international patent estate further strengthens our ability to pursue global opportunities and potentially partner with larger pharmaceutical companies for worldwide commercialization”. The rest of the shelf holds “an ovarian cancer immunotherapy being developed in collaboration with Moffitt Cancer Center”, built on “a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology”, in which “the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment”, plus “additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate”. One clause of the small print deserves its own line: “Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies”.
Then there is the market’s ledger, read four months on. A stock screener page updated October 30, 2026 has the shares at $3.12, down 5.45% on the day, with a market capitalization of $108.46M as of November 3, 2026 and 34,763,802 shares outstanding, a range for the year between $2.32 and $5.46, and the blunt summary that “It is currently -42.86% from its 52-week high and 34.48% from its 52-week low”. The page’s own verdicts are not kind. “ANIX is poor value based on its book value relative to its share price”, and on its discounted-cash-flow arithmetic “ANIX ($3.12) is overvalued by 9,636.2% relative to our estimate of its Fair Value price of $0.03 based on Discounted Cash Flow (DCF) modelling”. The site’s Zen Rating sits at D, on the reasoning that “Stocks with a Zen Rating of Sell ( D ) had an average loss of -6.47% per year”, and its due-diligence summary reports that “Overall, this stock passed 5 / 33 due dilligence checks and has weak fundamentals”. Notably, the same page allows that “ANIX’s cash and short-term investments ($13.86M) can cover ANIX’s cash burn ($7.38M) for at least 1 year”. The longer memory is the roughest line of all: “Anixa Biosciences stock was originally listed at a price of $87.50 in Dec 31, 1997”, since when “your return over the last 28 years would have been -96.43%”, “for an annualized return of -11.22%”. The clinic’s royalties, it would seem, are the steadier income stream.
Since Seoul, the news feed has kept its rhythm. By late October, “Anixa Biosciences Announces Completion of Treatment of Fifth Cohort in its Ovarian Cancer CAR-T Clinical Trial”, a milestone in the Moffitt collaboration, which earlier in the year could report that “Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial”. The patent family grew as well: “Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040”, a Canadian step under “Anixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance”, and a Mexican grant, “Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology”. For all the noise of a dozen announcements, the release’s own caution has not moved: “Breast cancer remains the most commonly diagnosed cancer among women worldwide, and currently there is no approved vaccine to prevent it”. The salient point, reading the two documents together, is a matter of clocks: the patents run to 2040, the trials are still climbing cohorts, and the distance between those two timers is exactly where the risk lives.
Sources
- Anixa Biosciences Stock Price Today (NASDAQ: ANIX) Quote, Market Cap, Chart | WallStreetZen
- Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040 PR Newswire
